Rapid generation of healthcare data and investment in digital health, EHRs, IOTs etc. is
increasing demand of clinical interpretations and real world evidence among clinicians
Healthcare in emerging markets requires solving first principles poor diagnosis, delayed
diagnosis, gut based treatment, compliance gaps all of which can be solved through
healthcare data and RWE
Large focus on branded generics across India and other emerging markets warrants discussion on new and original insights to capture mindshare among clinicians
Pandemic has led to significant disruption to RCTs and RWE is seeing sudden traction to understand burden by patient phenotype, and potential therapies for COVID 19
RWE in India continues to run as pilots across most companies, and therefore taking RWE leap helps stand out , esp. in crowded therapies